Pharmacokinetics of orally-administered Nicotinamide Powder 10% Zonne and its NAD+ pathway metabolites

Pharmacokinetics of orally-administered Nicotinamide Powder 10% Zonne and its NAD+ pathway metabolites - Pharmacokinetics of vitamin B3 and NAD+ metabolites in blood and urine

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031610

Enrollment

Registered

2018-03-06

Start date

2018-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

A single oral administration of Nicotinamide Powder 10% Zonne containing 200 mg of nicotinamide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those who agree to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those who take supplements containing vitamin B3 and wish to continue during the trial. 2. Those who are potentially pregnant. 3. Those who are under lactation. 4. Those who are under treatment. 5. Those judged by doctors or researchers to be inappropriate to participation in research.

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics of NAD+ in the blood and urine following the single administration of the drug	—

Secondary

Measure	Time frame
Pharmacokinetics of nicotinamide in the blood and urine following the single administration of the drug Safety evaluation with liver function monitoring	—

Countries

Japan

Contacts

Public ContactTakashi Ito

Hamamatsu University School of Medicine Department of Cellular and Molecular Anatomy

itotk777@hama-med.ac.jp053-435-2086

Outcome results